Systematic review and meta-analysis comparing the autogenous vein bypass versus a prosthetic graft for above-the-knee femoropopliteal bypass surgery in patients with intermittent claudication

医学 外科 间歇性跛行 严重肢体缺血 跛行 临床终点 人口 随机对照试验 大隐静脉 静脉 血管疾病 动脉疾病 环境卫生
作者
Rianne Vossen,TM Fokkema,A.C. Vahl,Ron Balm
出处
期刊:Vascular [SAGE Publishing]
卷期号:: 170853812211247-170853812211247 被引量:3
标识
DOI:10.1177/17085381221124701
摘要

According to guidelines, the autogenous saphenous vein (ASV) is the preferred conduit for femoropopliteal bypass surgery in all patients with peripheral artery disease. However, in contrast to patients with critical limb ischemia (CLI), patients with intermittent claudication (IC) only, tend to have milder disease, and thus a prosthetic graft may be as good as a vein conduit. The objective of this study was to compare patency rates of the ASV and a prosthetic graft in femoropopliteal bypass surgery in patients with IC.A systematic literature search was performed in the PubMed, Embase, and Cochrane databases to identify randomized controlled trials comparing prosthetic graft versus ASV in patients with IC. Articles with a mixed IC and CLI study population were included if more than 50% of the study cohort was treated for IC. Primary analysis was performed on IC patients only. Secondary analysis was performed on the mixed group. The primary endpoint was short- and long-term patency and secondary endpoints were complications, limb salvage, and mortality.In total, six studies with 524 patients were included. Only two studies reported solely on patients with IC. All these patients underwent above-the-knee bypasses and average patency rates at one and 5 years were 88% and 76% vs 81% and 68% in the ASV and the PTFE groups, respectively. One and five-year patency was not statistically different between the groups (OR 5.21; 95% CI 0.60-45.36 and OR 2.10; 95% CI 0.88-5.01). In a mixed population of patients with IC and CLI (84% IC patients), 1 year patency was comparable (OR 1.40; 95% CI 0.87-2.25). However, after a follow-up of over 3 years, this mixed group had significantly higher patency rates in favour of the ASV (OR 2.06; 95 % CI 1.30-3.26). Complication and amputation rates were comparable in both groups.Limited data are available for patients receiving above-the-knee femoropopliteal bypass for intermittent claudication. The ASV remains the conduit of choice for femoropopliteal bypass surgery. However, the prosthetic conduit seems a feasible alternative for patients with intermittent claudication in whom the ASV is not present or unsuitable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
诚心靳完成签到,获得积分10
刚刚
可爱的函函应助ws采纳,获得10
1秒前
wzwz完成签到,获得积分10
1秒前
君临梅阿查完成签到,获得积分10
1秒前
冷静新烟完成签到 ,获得积分10
1秒前
鑫博发布了新的文献求助10
2秒前
ding应助孟孟采纳,获得10
2秒前
爆米花应助黄慧采纳,获得10
2秒前
2秒前
2秒前
3秒前
SUMI完成签到,获得积分10
3秒前
对映体完成签到,获得积分10
3秒前
Owen应助哲水圣采纳,获得10
4秒前
My_magnum_opus应助深霖阳光采纳,获得30
4秒前
5秒前
5秒前
帅子完成签到,获得积分10
6秒前
阔达的盼海完成签到,获得积分20
6秒前
7秒前
复杂又夏发布了新的文献求助10
7秒前
丘比特应助XiaoNing采纳,获得10
7秒前
7秒前
FashionBoy应助鲤鱼雪巧采纳,获得10
7秒前
小阿操发布了新的文献求助10
8秒前
对映体发布了新的文献求助10
9秒前
10秒前
Wanying_Diao完成签到,获得积分10
10秒前
juanjuan发布了新的文献求助10
10秒前
大意的土豆完成签到,获得积分10
11秒前
12秒前
缥缈斌发布了新的文献求助10
12秒前
maiyatang完成签到,获得积分10
12秒前
自然酬海发布了新的文献求助10
12秒前
一九九七发布了新的文献求助10
12秒前
13秒前
t65t6y完成签到,获得积分10
14秒前
14秒前
456完成签到,获得积分10
15秒前
鲨鱼发布了新的文献求助10
15秒前
高分求助中
Markov Chain Monte Carlo 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Common Foundations of American and East Asian Modernisation: From Alexander Hamilton to Junichero Koizumi 5000
Pediatric Dermoscopy Trichoscopy & Onychoscopy 1000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
Data book on fatigue strength of metallic materials 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7567647
求助须知:如何正确求助?哪些是违规求助? 9147653
关于积分的说明 19561655
捐赠科研通 7153743
什么是DOI,文献DOI怎么找? 3262903
关于科研通互助平台的介绍 2429017
邀请新用户注册赠送积分活动 2252998